News & Media

Launch Date: 30/06/2021

Aprazer Healthcare Launched PIRFEKAST (Pirfenidone) which is a medication indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

With a vision to make affordable & quality oncology medicines Aprazer healthcare will manufacture world class oncology drugs at state of art WHO-GMP manufacturing facility capable of making solid orals ( Tablets & Capsules ) & small volume parenteral, lyophilized injections at Himachal Pradesh spanning in area of 18000 Sq meters.

Launch Date: 26/02/21

Aprazer Healthcare Launched SUTEKAST (Sunitinib) which is a medication indicated for the treatment of rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. SUTEKAST is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma or RCC). SUTEKAST is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. SUTEKAST is indicated for the treatment of pancreatic neuroendocrine tumors (pNET) with progression & cannot be treated with surgery.

Launch Date: 11/01/21

Aprazer Healthcare Launched XGRAF (Tacrolimus Capsules ) which is used for the prophylaxis of organ rejection in adults and paediatric patients receiving kidney transplant, liver transplant and heart transplant, in combination with other immunosuppressant’s.

Launch Date: 19/12/20

Aprazer Healthcare Launched MEROAXIS (Meropenem Inj) which is a medication indicated for the treatment of susceptible infections including intra-abdominal infections, meningitis, respiratory tract infections (Including cystic fibrosis patients) septicemia, skin infections, urinary tract infections and infections in immune-compromised patients.

Launch Date: 07/12/20

Aprazer Healthcare Launched HQKAST (Hydroxychloroquine), which is a medication indicated for the treatment of Malaria, Whipple’s Disease, Rheumatoid Disease

Launch Date: 31/10/20

Aprazer Healthcare Launched CAPEKAST (Capecitabine) which is a medication indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.

Launch Date: 17/10/20

Aprazer Healthcare Launched Lenvakast (Lenvatinib) which is a medication indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). LENVAKAST is indicated for the 1st-line treatment of patients with unresectable hepatocellular carcinoma. LENVAKAST is also indicated for Renal Cell Carcinoma. LENVAKAST is also indicated for Endometrial Carcinoma.

Launch Date: 29/09/2020

Aprazer Healthcare Launched Lenakast (Lenalidomide) which is a medication indicated for the treatment of Myelodysplastic Syndromes Multiple Myeloma in combination with Dexamethasone, Mantle Cell Lymphoma and  Follicular Lymphoma or Marginal Zone Lymphoma.

Launch Date: 31/08/20

Aprazer Healthcare Launched TAMIKAST (Oseltamivir) which is a medication indicated for the treatment of Influenza Infection and Prophylaxis

Launch Date: 29/08/20

Aprazer Healthcare Launched INLYBEST (Axitinib) which is a medication indicated for the treatment of Advanced Renal Cell Carcinoma and Hepatocellular carcinoma.

Launch Date: 10/08/20

Aprazer Healthcare Launched OCABEST (Obeticholic Acid ) which is a medication indicated for the treatment of Primary Biliary Cirrhosis who have not responded to UDCA treatment.